儿童心脏手术中抑肽酶与氨甲环酸的观察性研究
该回顾性研究纳入2002至2015年单中心2157例儿童心脏手术患者,比较抑肽酶组(2002-2007年,1136例)与氨甲环酸组(2008-2015年,1021例)。倾向性评分分析显示抑肽酶组血制品暴露率更高(78% vs 60%,P<0.001),严重术后并发症或死亡率更高(33% vs 28%,P=0.007),高危亚组未见获益。
要点
- 抑肽酶组血制品暴露率显著高于氨甲环酸组(78% vs 60%,P<0.001)。
- 抑肽酶组严重术后并发症或死亡率更高(33% vs 28%,P=0.007)。
- 新生儿、复杂手术及再次手术等高危亚组未从抑肽酶中获益。
核心结论
- 儿童心脏手术中接受抑肽酶者输血更频繁且严重术后并发症或死亡风险更高。
- 高危出血或炎症亚组未见抑肽酶获益。
- 差异可能源于氨甲环酸更安全及多年患者血液管理策略变化。
研究设计与样本
- 回顾性研究,2002至2015年三级儿童医院单中心。
- 抑肽酶组1136例(2002-2007年),氨甲环酸组1021例(2008-2015年),共2157例。
- 采用倾向性评分分析比较两组。
- 主要结局为血制品暴露和严重术后并发症或死亡。
- 分析新生儿、复杂手术(RACHS-1≥3)及再次手术高危亚组。
主要发现
- 抑肽酶组血制品暴露率78% vs 氨甲环酸组60%(P<0.001),复杂手术和再次手术亚组同样更高。
- 抑肽酶组死亡和/或严重并发症发生率33% vs 28%(P=0.007),新生儿亚组同样更高。
- 氨甲环酸组体外循环预充量和术中液体平衡显著降低,改良超滤使用显著增加。
临床怎么用
- 儿童心脏手术优先选用氨甲环酸而非抑肽酶以减少输血和严重并发症风险。
- 新生儿、复杂手术及再次手术等高危患者不应期望从抑肽酶获益。
- 需结合患者血液管理策略综合评估止血药物选择。
局限性
- 回顾性观察性研究,组间存在时间跨度差异(2002-2007 vs 2008-2015)。
- 差异可能部分归因于多年患者血液管理策略的重大变化而非药物本身。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The upcoming release of aprotinin in paediatric cardiac surgery prompted a re-evaluation of its use in comparison to tranexamic acid (TXA) focusing on their effect on exposure to blood transfusions as well as severe postoperative morbidity or mortality. METHODS: This retrospective study was conducted in a tertiary children hospital from 2002 to 2015. Patients receiving aprotinin (Aprotinin group: 2002-2007) were compared with those receiving TXA group (2008-2015) using propensity score analysis. Primary outcome measures were 'exposure to blood products' and 'severe postoperative morbidity or mortality'. High-risk subgroups that included neonates, complex (Risk Adjusted Classification for Congenital Heart Surgery-1 ≥ 3) and redo surgery were also analysed. RESULTS: The study included 2157 patients, 1136 in the Aprotinin group and 1021 in the TXA group. Exposure to blood products was significantly higher in the Aprotinin group (78% vs 60%; P < 0.001) as well as in the complex and redo surgery subgroups. Incidence of mortality and/or severe morbidity was higher in the Aprotinin group (33% vs 28%; P = 0.007), as well as in the neonate group. However, cardiopulmonary bypass priming volume and intraoperative fluid balance were significantly decreased, and the use of modified ultrafiltration significantly increased in the TXA group. CONCLUSIONS: In our population, children receiving aprotinin were more frequently transfused and were at a higher risk of developing severe postoperative morbidity or mortality than those receiving TXA. Subgroups at high risk of bleeding or inflammation did not seem to benefit from aprotinin. These differences might be explained by a safer profile of TXA, but also attributed to major changes in our patient blood management strategies over years.
引用
- Willems A, De Groote F, Dumoulin M, et al. Aprotinin versus tranexamic acid in children undergoing cardiac surgery: an observational study. Eur J Cardiothorac Surg. 2019. PMID: 30928999. doi:10.1093/ejcts/ezz088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。